ZYME Zymeworks Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1937653 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY97.8%
TTM net income YoY168.3%
TTM EPS YoY162.4%
Revenue 3-yr CAGR-16.8%
Net income 3-yr CAGR-40.5%
Margins
Gross margin—
Operating margin16.6%
Net margin16.3%
FCF margin-42.4%
EBITDA margin18.0%
Returns
ROE15.0%
ROA5.5%
ROIC (approx.)11.7%
Asset turnover0.34x
Leverage & solvency
Liabilities / assets78.0%
Debt / equity1.31x
Current ratio3.30x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-2.59x
Accruals ratio19.7%
Payout ratio—
Capex / revenue0.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $105.97M | $76.30M |
| R&D expense | $137.00M | $134.62M |
| SG&A expense | $61.51M | $61.51M |
| Operating income | -$92.55M | -$137.11M |
| Pretax income | -$79.75M | -$116.61M |
| Income tax | $1.38M | $6.08M |
| Net income | -$81.13M | -$122.69M |
| EBITDA | -$88.88M | -$132.92M |
| EPS (basic) | -1.08 | -1.62 |
| EPS (diluted) | -1.08 | -1.62 |
| Weighted avg. shares (diluted) | 75.41M | 75.88M |
| Balance sheet | ||
| Cash & equivalents | $41.16M | $66.10M |
| Receivables | $4.64M | $55.81M |
| Current assets | $248.77M | $300.45M |
| PP&E, net | $15.50M | $17.65M |
| Goodwill | $12.02M | $12.02M |
| Intangibles | $1.35M | $4.58M |
| Total assets | $346.53M | $463.09M |
| Current liabilities | $42.32M | $88.29M |
| Total liabilities | $78.03M | $124.32M |
| Shareholders' equity | $268.50M | $338.77M |
| Shares outstanding | 74.64M | 68.96M |
| Cash flow statement | ||
| Operating cash flow | -$33.01M | -$110.06M |
| Capital expenditure | $1.52M | $1.99M |
| Free cash flow | -$34.53M | -$112.05M |
| Investing cash flow | $26.66M | $38.76M |
| Financing cash flow | -$18.56M | -$20.44M |
| Depreciation & amortization | $3.67M | $4.19M |
| Stock-based compensation | $28.03M | $17.79M |
| Share buybacks | $41.70M | $30.05M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.